Evolus’ (EOLS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Evolus (NASDAQ:EOLS) in a research report released on Friday, Benzinga reports. The brokerage currently has a $27.00 price objective on the stock.

Other equities analysts also recently issued reports about the company. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Evolus in a research report on Friday, September 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a report on Monday, September 16th. Finally, Barclays lifted their target price on shares of Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th.

Evolus Stock Down 2.0 %

Shares of NASDAQ:EOLS opened at $16.42 on Friday. Evolus has a 52-week low of $7.74 and a 52-week high of $17.82. The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 6.26. The company has a fifty day moving average of $16.26 and a 200-day moving average of $13.77.

Insider Buying and Selling at Evolus

In other news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the sale, the chief marketing officer now owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the sale, the chief marketing officer now directly owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the sale, the chief financial officer now owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in EOLS. Quest Partners LLC bought a new stake in Evolus in the second quarter worth approximately $43,000. Quarry LP acquired a new stake in shares of Evolus during the 2nd quarter worth approximately $54,000. Profund Advisors LLC bought a new stake in shares of Evolus in the 2nd quarter valued at $130,000. Arizona State Retirement System lifted its position in shares of Evolus by 9.4% during the 2nd quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock valued at $158,000 after acquiring an additional 1,253 shares during the period. Finally, ProShare Advisors LLC boosted its stake in Evolus by 9.9% during the first quarter. ProShare Advisors LLC now owns 11,542 shares of the company’s stock worth $162,000 after acquiring an additional 1,035 shares in the last quarter. 90.69% of the stock is owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.